{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:48:01Z","timestamp":1791110881495,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T00:00:00Z","timestamp":1639008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T00:00:00Z","timestamp":1639008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2022,3,23]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with metastatic colorectal cancer (mCRC) carrying <jats:italic>BRAF<\/jats:italic> (mut<jats:italic>BRAF<\/jats:italic>) or <jats:italic>KRAS<\/jats:italic> mutation (mut<jats:italic>KRAS<\/jats:italic>) have an inferior prognosis after liver or lung surgery, whereas the prognostic role in the context of peritoneal metastasis (PM) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has been less investigated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In total, 257 patients with non-appendiceal PM-CRC were included from the Norwegian National Unit for CRS-HIPEC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 180 patients received CRS<jats:bold>-<\/jats:bold>HIPEC with Mitomycin C, 77 patients received palliative surgery only. In the CRS-HIPEC group, mut<jats:italic>BRAF<\/jats:italic> was found in 24.7%, mut<jats:italic>KRAS<\/jats:italic> 33.9% and double wild-type 41.4% without differences in survival. MSI was found in 29.3% of mut<jats:italic>BRAF<\/jats:italic> cases. Patients with mut<jats:italic>BRAF\/<\/jats:italic>MSI had superior 5-year survival compared to mut<jats:italic>BRAF<\/jats:italic> with MSS (58.3% vs 25.2%, <jats:italic>P<\/jats:italic>\u2009=\u20090.022), and better 3-year disease-free survival (DFS) compared to mut<jats:italic>KRAS<\/jats:italic> (48.6% vs 17.2%, <jats:italic>P<\/jats:italic>\u2009=\u20090.049). Peritoneal Cancer Index and the number of lymph node metastasis were prognostic for OS, and the same two, location and gender prognostic for DFS in multivariate analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>PM-CRC with CRS-HIPEC patients has a surprisingly high proportion of mut<jats:italic>BRAF<\/jats:italic> (24.7%). Survival was similar comparing mut<jats:italic>BRAF<\/jats:italic>, mut<jats:italic>KRAS<\/jats:italic> and double wild-type cases, whereas a small subgroup with mut<jats:italic>BRAF<\/jats:italic> and MSI had better survival. Patients with mut<jats:italic>BRAF<\/jats:italic> tumours and limited PM should be considered for CRS-HIPEC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41416-021-01620-6","type":"journal-article","created":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T16:02:53Z","timestamp":1639065773000},"page":"726-735","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients"],"prefix":"10.1038","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9831-1995","authenticated-orcid":false,"given":"S. G.","family":"Larsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Goscinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Dueland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. E.","family":"Steigen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Hofsli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Torgunrud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lund-Iversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. J.","family":"Dagenborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Flatmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Sorbye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,9]]},"reference":[{"key":"1620_CR1","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA: A Cancer J Clin"},{"key":"1620_CR2","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/01.sla.0000217629.94941.cf","volume":"244","author":"S Manfredi","year":"2006","unstructured":"Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244:254\u20139.","journal-title":"Ann Surg"},{"key":"1620_CR3","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1097\/DCR.0b013e3182a62d9d","volume":"56","author":"I Thomassen","year":"2013","unstructured":"Thomassen I, van Gestel YR, Lemmens VE, de Hingh IH. Incidence, prognosis, and treatment options for patients with synchronous peritoneal carcinomatosis and liver metastases from colorectal origin. Dis Colon Rectum. 2013;56:1373\u201380.","journal-title":"Dis Colon Rectum"},{"key":"1620_CR4","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/archsurg.1992.01420120037006","volume":"127","author":"PM McCormack","year":"1992","unstructured":"McCormack PM, Burt ME, Bains MS, Martini N, Rusch VW, Ginsberg RJ. Lung resection for colorectal metastases. 10-year results. Arch Surg. 1992;127:1403\u20136.","journal-title":"Arch Surg"},{"key":"1620_CR5","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.canep.2014.04.004","volume":"38","author":"YR van Gestel","year":"2014","unstructured":"van Gestel YR, de Hingh IH, van Herk-Sukel MP, van Erning FN, Beerepoot LV, Wijsman JH, et al. Patterns of metachronous metastases after curative treatment of colorectal cancer. Cancer Epidemiol. 2014;38:448\u201354.","journal-title":"Cancer Epidemiol"},{"key":"1620_CR6","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","volume":"17","author":"J Franko","year":"2016","unstructured":"Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016;17:1709\u201319.","journal-title":"Lancet Oncol"},{"key":"1620_CR7","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1200\/JCO.2008.20.5278","volume":"27","author":"S Kopetz","year":"2009","unstructured":"Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27:3677\u201383.","journal-title":"J Clin Oncol"},{"key":"1620_CR8","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1200\/JCO.2011.38.0915","volume":"30","author":"KM Tveit","year":"2012","unstructured":"Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol. 2012;30:1755\u201362.","journal-title":"J Clin Oncol"},{"key":"1620_CR9","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1093\/annonc\/mdt197","volume":"24","author":"H Sorbye","year":"2013","unstructured":"Sorbye H, Cvancarova M, Qvortrup C, Pfeiffer P, Glimelius B. Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer. Ann Oncol. 2013;24:2354\u201360.","journal-title":"Ann Oncol"},{"key":"1620_CR10","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s00384-020-03525-x","volume":"35","author":"O Abdel-Rahman","year":"2020","unstructured":"Abdel-Rahman O. A real-world, population-based study of the outcomes of patients with metastatic colorectal cancer to the peritoneum treated with or without cytoreductive surgery. Int J Colorectal Dis. 2020;35:719\u201325.","journal-title":"Int J Colorectal Dis"},{"key":"1620_CR11","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","volume":"15","author":"VJ Verwaal","year":"2008","unstructured":"Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15:2426\u201332.","journal-title":"Ann Surg Oncol"},{"key":"1620_CR12","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1200\/JCO.2008.19.7160","volume":"27","author":"D Elias","year":"2009","unstructured":"Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681\u20135.","journal-title":"J Clin Oncol"},{"key":"1620_CR13","doi-asserted-by":"publisher","first-page":"3756","DOI":"10.1002\/cncr.25116","volume":"116","author":"J Franko","year":"2010","unstructured":"Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh HJ 3rd. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer. 2010;116:3756\u201362.","journal-title":"Cancer."},{"key":"1620_CR14","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/sj.bjc.6601586","volume":"90","author":"H Mahteme","year":"2004","unstructured":"Mahteme H, Hansson J, Berglund A, Pahlman L, Glimelius B, Nygren P, et al. Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study. Br J Cancer. 2004;90:403\u20137.","journal-title":"Br J Cancer"},{"key":"1620_CR15","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/bjc.2014.419","volume":"111","author":"R Mirnezami","year":"2014","unstructured":"Mirnezami R, Mehta AM, Chandrakumaran K, Cecil T, Moran BJ, Carr N, et al. Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone. Br J Cancer. 2014;111:1500\u20138.","journal-title":"Br J Cancer"},{"key":"1620_CR16","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/jso.24290","volume":"114","author":"IS Froysnes","year":"2016","unstructured":"Froysnes IS, Larsen SG, Spasojevic M, Dueland S, Flatmark K. Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: prognostic factors and oncologic outcome in a national patient cohort. J Surg Oncol. 2016;114:222\u20137.","journal-title":"J Surg Oncol"},{"key":"1620_CR17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1200\/JCO.2011.37.1039","volume":"30","author":"J Franko","year":"2012","unstructured":"Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012;30:263\u20137.","journal-title":"J Clin Oncol"},{"key":"1620_CR18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3109\/07357907.2012.654871","volume":"30","author":"BL Brucher","year":"2012","unstructured":"Brucher BL, Piso P, Verwaal V, Esquivel J, Derraco M, Yonemura Y, et al. Peritoneal carcinomatosis: cytoreductive surgery and HIPEC\u2013overview and basics. Cancer Investig. 2012;30:209\u201324.","journal-title":"Cancer Investig"},{"key":"1620_CR19","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1245\/s10434-017-6141-7","volume":"25","author":"G Passot","year":"2018","unstructured":"Passot G, Kim BJ, Glehen O, Mehran RJ, Kopetz SE, Goere D, et al. Impact of RAS mutations in metastatic colorectal cancer after potentially curative resection: does site of metastases matter? Ann Surg Oncol. 2018;25:179\u201387.","journal-title":"Ann Surg Oncol"},{"key":"1620_CR20","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/bjc.2014.499","volume":"112","author":"S Renaud","year":"2015","unstructured":"Renaud S, Romain B, Falcoz PE, Olland A, Santelmo N, Brigand C, et al. KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer. Br J Cancer. 2015;112:720\u20138.","journal-title":"Br J Cancer"},{"key":"1620_CR21","doi-asserted-by":"publisher","first-page":"e0131046","DOI":"10.1371\/journal.pone.0131046","volume":"10","author":"H Sorbye","year":"2015","unstructured":"Sorbye H, Dragomir A, Sundstrom M, Pfeiffer P, Thunberg U, Bergfors M, et al. High BRAF mutation frequency and marked survival differences in subgroups according to KRAS\/BRAF mutation status and tumor tissue availability in a prospective population-based metastatic colorectal cancer cohort. PLoS ONE. 2015;10:e0131046.","journal-title":"PLoS ONE"},{"key":"1620_CR22","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1097\/SLA.0000000000002899","volume":"268","author":"MA Schneider","year":"2018","unstructured":"Schneider MA, Eden J, Pache B, Laminger F, Lopez-Lopez V, Steffen T, et al. Mutations of RAS\/RAF proto-oncogenes impair survival after cytoreductive surgery and HIPEC for peritoneal metastasis of colorectal origin. Ann Surg. 2018;268:845\u201353.","journal-title":"Ann Surg"},{"key":"1620_CR23","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1002\/cncr.28729","volume":"120","author":"R Yaeger","year":"2014","unstructured":"Yaeger R, Cercek A, Chou JF, Sylvester BE, Kemeny NE, Hechtman JF, et al. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer. 2014;120:2316\u201324.","journal-title":"Cancer."},{"key":"1620_CR24","doi-asserted-by":"publisher","first-page":"e180996","DOI":"10.1001\/jamasurg.2018.0996","volume":"153","author":"GA Margonis","year":"2018","unstructured":"Margonis GA, Buettner S, Andreatos N, Kim Y, Wagner D, Sasaki K, et al. Association of BRAF mutations with survival and recurrence in surgically treated patients with metastatic colorectal liver cancer. JAMA Surg. 2018;153:e180996.","journal-title":"JAMA Surg"},{"key":"1620_CR25","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1016\/j.clcc.2017.10.006","volume":"17","author":"H Kayhanian","year":"2018","unstructured":"Kayhanian H, Goode E, Sclafani F, Ang JE, Gerlinger M, Gonzalez de Castro D, et al. Treatment and survival outcome of BRAF-mutated metastatic colorectal cancer: a retrospective matched case-control study. Clin Colorectal Cancer. 2018;17:e69\u2013e76.","journal-title":"Clin Colorectal Cancer"},{"key":"1620_CR26","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/SLA.0000000000002968","volume":"271","author":"J Gagni\u00e8re","year":"2020","unstructured":"Gagni\u00e8re J, Dupr\u00e9 A, Gholami SS, Pezet D, Boerner T, G\u00f6nen M, et al. Is hepatectomy justified for BRAF mutant colorectal liver metastases?: a multi-institutional analysis of 1497 patients. Ann Surg. 2020;271:147\u201354.","journal-title":"Ann Surg"},{"key":"1620_CR27","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/sj.bjc.6604867","volume":"100","author":"M Koopman","year":"2009","unstructured":"Koopman M, Kortman GA, Mekenkamp L, Ligtenberg MJ, Hoogerbrugge N, Antonini NF, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer. 2009;100:266\u201373.","journal-title":"Br J Cancer"},{"key":"1620_CR28","doi-asserted-by":"publisher","first-page":"5322","DOI":"10.1158\/1078-0432.CCR-14-0332","volume":"20","author":"S Venderbosch","year":"2014","unstructured":"Venderbosch S, Nagtegaal ID, Maughan TS, Smith CG, Cheadle JP, Fisher D, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res. 2014;20:5322\u201330.","journal-title":"Clin Cancer Res"},{"key":"1620_CR29","doi-asserted-by":"publisher","first-page":"3623","DOI":"10.1002\/cam4.2205","volume":"8","author":"KO Aasebo","year":"2019","unstructured":"Aasebo KO, Dragomir A, Sundstrom M, Mezheyeuski A, Edqvist PH, Eide GE, et al. Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: a population-based cohort of metastatic colorectal cancer patients. Cancer Med. 2019;8:3623\u201335.","journal-title":"Cancer Med"},{"key":"1620_CR30","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","volume":"18","author":"MJ Overman","year":"2017","unstructured":"Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18:1182\u201391.","journal-title":"Lancet Oncol"},{"key":"1620_CR31","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1056\/NEJMcp1714533","volume":"379","author":"FA Sinicrope","year":"2018","unstructured":"Sinicrope FA. Lynch syndrome-associated colorectal cancer. The. N. Engl J Med. 2018;379:764\u201373.","journal-title":"N. Engl J Med"},{"key":"1620_CR32","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1245\/s10434-019-07452-2","volume":"27","author":"W Graf","year":"2020","unstructured":"Graf W, Cashin PH, Ghanipour L, Enblad M, Botling J, Terman A, et al. Prognostic impact of BRAF and KRAS mutation in patients with colorectal and appendiceal peritoneal metastases scheduled for CRS and HIPEC. Ann Surg Oncol. 2020;27:293\u2013300.","journal-title":"Ann Surg Oncol"},{"key":"1620_CR33","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1245\/s10434-007-9635-x","volume":"15","author":"L Benoit","year":"2008","unstructured":"Benoit L, Cheynel N, Ortega-Deballon P, Giacomo GD, Chauffert B, Rat P. Closed hyperthermic intraperitoneal chemotherapy with open abdomen: a novel technique to reduce exposure of the surgical team to chemotherapy drugs. Ann Surg Oncol. 2008;15:542\u20136.","journal-title":"Ann Surg Oncol"},{"key":"1620_CR34","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/SLA.0b013e3181afde41","volume":"250","author":"SM Strasberg","year":"2009","unstructured":"Strasberg SM, Linehan DC, Hawkins WG. The accordion severity grading system of surgical complications. Ann Surg. 2009;250:177\u201386.","journal-title":"Ann Surg"},{"key":"1620_CR35","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/bjc.2017.93","volume":"116","author":"TK Guren","year":"2017","unstructured":"Guren TK, Thomsen M, Kure EH, Sorbye H, Glimelius B, Pfeiffer P, et al. Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study. Br J Cancer. 2017;116:1271\u20138.","journal-title":"Br J Cancer"},{"key":"1620_CR36","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1038\/nprot.2015.105","volume":"10","author":"H Yang","year":"2015","unstructured":"Yang H, Wang K. Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR. Nat Protoc. 2015;10:1556\u201366.","journal-title":"Nat Protoc"},{"key":"1620_CR37","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1056\/NEJMc0904160","volume":"361","author":"J Tol","year":"2009","unstructured":"Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. N. Engl J Med. 2009;361:98\u20139.","journal-title":"N. Engl J Med"},{"key":"1620_CR38","first-page":"645","volume":"6","author":"M Lipsyc","year":"2015","unstructured":"Lipsyc M, Yaeger R. Impact of somatic mutations on patterns of metastasis in colorectal cancer. J Gastrointest Oncol. 2015;6:645\u20139.","journal-title":"J Gastrointest Oncol"},{"key":"1620_CR39","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/SLA.0000000000002319","volume":"269","author":"KW Brudvik","year":"2019","unstructured":"Brudvik KW, Jones RP, Giuliante F, Shindoh J, Passot G, Chung MH, et al. RAS mutation clinical risk score to predict survival after resection of colorectal liver metastases. Ann Surg. 2019;269:120\u20136.","journal-title":"Ann Surg"},{"key":"1620_CR40","doi-asserted-by":"publisher","first-page":"6147","DOI":"10.21037\/jtd.2018.10.72","volume":"10","author":"T Schweiger","year":"2018","unstructured":"Schweiger T, Liebmann-Reindl S, Glueck O, Starlinger P, Laengle J, Birner P, et al. Mutational profile of colorectal cancer lung metastases and paired primary tumors by targeted next generation sequencing: implications on clinical outcome after surgery. J Thorac Dis. 2018;10:6147\u201357.","journal-title":"J Thorac Dis"},{"key":"1620_CR41","doi-asserted-by":"publisher","first-page":"e204","DOI":"10.1002\/bjs.10788","volume":"105","author":"I Ubink","year":"2018","unstructured":"Ubink I, van Eden WJ, Snaebjornsson P, Kok NFM, van Kuik J, van Grevenstein WMU, et al. Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases. Br J Surg. 2018;105:e204\u2013e11.","journal-title":"Br J Surg"},{"key":"1620_CR42","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/1097-0142(19890115)63:2<364::AID-CNCR2820630228>3.0.CO;2-V","volume":"63","author":"DZ Chu","year":"1989","unstructured":"Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer. 1989;63:364\u20137.","journal-title":"Cancer."},{"key":"1620_CR43","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1093\/jnci\/djt173","volume":"105","author":"P Lochhead","year":"2013","unstructured":"Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamauchi M, Nishihara R, et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst. 2013;105:1151\u20136.","journal-title":"J Natl Cancer Inst"},{"key":"1620_CR44","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1016\/j.clcc.2019.09.003","volume":"19","author":"TH Brunsell","year":"2020","unstructured":"Brunsell TH, Sveen A, Bj\u00f8rnbeth BA, R\u00f8sok BI, Danielsen SA, Brudvik KW, et al. High concordance and negative prognostic impact of RAS\/BRAF\/PIK3CA mutations in multiple resected colorectal liver metastases. Clin Colorectal Cancer. 2020;19:e26\u2013e47.","journal-title":"Clin Colorectal Cancer"},{"key":"1620_CR45","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1038\/bjc.2015.142","volume":"112","author":"M Schirripa","year":"2015","unstructured":"Schirripa M, Bergamo F, Cremolini C, Casagrande M, Lonardi S, Aprile G, et al. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. Br J Cancer. 2015;112:1921\u20138.","journal-title":"Br J Cancer"},{"key":"1620_CR46","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1002\/bjs.11180","volume":"106","author":"JB Bachet","year":"2019","unstructured":"Bachet JB, Moreno-Lopez N, Vigano L, Marchese U, Gelli M, Raoux L, et al. BRAF mutation is not associated with an increased risk of recurrence in patients undergoing resection of colorectal liver metastases. Br J Surg. 2019;106:1237\u201347.","journal-title":"Br J Surg"},{"key":"1620_CR47","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1245\/s10434-019-07935-2","volume":"27","author":"D Baratti","year":"2020","unstructured":"Baratti D, Kusamura S, Niger M, Perrone F, Milione M, Cattaneo L, et al. Prognostic impact of primary side and RAS\/RAF mutations in a surgical series of colorectal cancer with peritoneal metastases. Ann Surg Oncol. 2020;27:98\u2013106.","journal-title":"Ann Surg Oncol"},{"key":"1620_CR48","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejca.2019.06.008","volume":"118","author":"F Loupakis","year":"2019","unstructured":"Loupakis F, Intini R, Cremolini C, Orlandi A, Sartore-Bianchi A, Pietrantonio F, et al. A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the \u2018BRAF BeCool\u2019 study. Eur J Cancer. 2019;118:121\u201330.","journal-title":"Eur J Cancer"},{"key":"1620_CR49","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1093\/annonc\/mdw645","volume":"28","author":"JF Seligmann","year":"2017","unstructured":"Seligmann JF, Fisher D, Smith CG, Richman SD, Elliott F, Brown S, et al. Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials. Ann Oncol. 2017;28:562\u20138.","journal-title":"Ann Oncol"},{"key":"1620_CR50","doi-asserted-by":"crossref","unstructured":"Taieb J, Le Malicot K, Shi Q, Penault-Llorca F, Bouch\u00e9 O, Tabernero J, et al. Prognostic value of BRAF and KRAS mutations in MSI and MSS stage III colon cancer. J Natl Cancer Inst. 2017;109:djw272.","DOI":"10.1093\/jnci\/djw272"},{"key":"1620_CR51","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamaoncol.2015.5225","volume":"2","author":"J Taieb","year":"2016","unstructured":"Taieb J, Zaanan A, Le Malicot K, Juli\u00e9 C, Blons H, Mineur L, et al. Prognostic effect of BRAF and KRAS mutations in patients with stage III colon cancer treated with leucovorin, fluorouracil, and oxaliplatin with or without cetuximab: a post hoc analysis of the PETACC-8 trial. JAMA Oncol. 2016;2:643\u201353.","journal-title":"JAMA Oncol"},{"key":"1620_CR52","doi-asserted-by":"publisher","first-page":"4623","DOI":"10.1002\/cncr.26086","volume":"117","author":"B Tran","year":"2011","unstructured":"Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011;117:4623\u201332.","journal-title":"Cancer."},{"key":"1620_CR53","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1245\/s10434-020-08733-x","volume":"27","author":"SK Sherman","year":"2020","unstructured":"Sherman SK, Schuitevoerder D, Chan CHF, Turaga KK. Metastatic colorectal cancers with mismatch repair deficiency result in worse survival regardless of peritoneal metastases. Ann Surg Oncol. 2020;27:5074\u201383.","journal-title":"Ann Surg Oncol"},{"key":"1620_CR54","doi-asserted-by":"publisher","first-page":"239","DOI":"10.21873\/anticanres.11313","volume":"37","author":"K Fujiyoshi","year":"2017","unstructured":"Fujiyoshi K, Yamamoto G, Takenoya T, Takahashi A, Arai Y, Yamada M, et al. Metastatic pattern of stage IV colorectal cancer with high-frequency microsatellite instability as a prognostic factor. Anticancer Res. 2017;37:239\u201347.","journal-title":"Anticancer Res"},{"key":"1620_CR55","doi-asserted-by":"publisher","first-page":"76290","DOI":"10.18632\/oncotarget.19350","volume":"8","author":"O \u00d8strup","year":"2017","unstructured":"\u00d8strup O, Dagenborg VJ, R\u00f8dland EA, Skarpeteig V, Silwal-Pandit L, Grzyb K, et al. Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases. Oncotarget. 2017;8:76290\u2013304.","journal-title":"Oncotarget."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01620-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01620-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01620-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T16:17:32Z","timestamp":1676045852000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01620-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,9]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,3,23]]}},"alternative-id":["1620"],"URL":"https:\/\/doi.org\/10.1038\/s41416-021-01620-6","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,9]]},"assertion":[{"value":"28 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Norwegian Ethics Committee (s-07160b), South-Eastern Norway Regional Health Authority, Hamar, Norway and written informed consent was obtained from the patients. Data are from our institutions peritoneal metastasis MedInSight database, Oslo University Hospital, Oslo, Norway. Base owner SL is Head of Oncological Surgery, The Norwegian Radium Hospital, and Chair of the National Service for CRS-HIPEC in Norway. The study is performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No individual person\u2019s data is included.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}